Carlton Meschievitz

4.5k total citations · 2 hit papers
24 papers, 3.3k citations indexed

About

Carlton Meschievitz is a scholar working on Epidemiology, Hepatology and Microbiology. According to data from OpenAlex, Carlton Meschievitz has authored 24 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Epidemiology, 9 papers in Hepatology and 8 papers in Microbiology. Recurrent topics in Carlton Meschievitz's work include Hepatitis C virus research (8 papers), Bacterial Infections and Vaccines (8 papers) and Pneumonia and Respiratory Infections (7 papers). Carlton Meschievitz is often cited by papers focused on Hepatitis C virus research (8 papers), Bacterial Infections and Vaccines (8 papers) and Pneumonia and Respiratory Infections (7 papers). Carlton Meschievitz collaborates with scholars based in United States, France and Australia. Carlton Meschievitz's co-authors include Janice K. Albrecht, Henry C. Bodenheimer, Alexandra L. Gibas, John A. Payne, Ira M. Jacobson, Carlo H. Tamburro, Jay H. Lefkowitch, Jules L. Dienstag, Robert P. Perrillo and Karen L. Lindsay and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Hepatology.

In The Last Decade

Carlton Meschievitz

24 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa

1989 1.4k citations Gary L. Davis, Luis A. Balart et al. New England Journal of Medicine profile →
A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B

1990 664 citations Robert P. Perrillo, E. Schiff et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carlton Meschievitz United States	18	2.7k	2.5k	430	426	195	24	3.3k
Massimo Resti Italy	32	2.3k 0.9×	1.6k 0.7×	346 0.8×	312 0.7×	289 1.5×	150	3.4k
Josep Costa Spain	29	2.4k 0.9×	2.1k 0.9×	114 0.3×	575 1.3×	109 0.6×	104	3.3k
Jacqueline C. Melpolder United States	9	2.6k 1.0×	2.9k 1.2×	212 0.5×	380 0.9×	23 0.1×	11	3.4k
Giuseppe Indolfi Italy	26	2.1k 0.8×	1.4k 0.6×	150 0.3×	351 0.8×	295 1.5×	170	2.9k
Jaime Guardia Spain	27	2.2k 0.8×	2.3k 0.9×	56 0.1×	301 0.7×	48 0.2×	58	2.9k
M. Chiaramonte Italy	26	1.5k 0.5×	1.5k 0.6×	123 0.3×	199 0.5×	41 0.2×	96	2.1k
R. Giacchino Italy	29	1.9k 0.7×	1.5k 0.6×	152 0.4×	214 0.5×	143 0.7×	112	2.7k
M. Rapicetta Italy	25	1.7k 0.6×	1.8k 0.7×	92 0.2×	366 0.9×	26 0.1×	83	2.6k
Andrzej Horban Poland	34	2.4k 0.9×	2.2k 0.9×	167 0.4×	2.1k 4.8×	49 0.3×	183	4.6k
Paul Dény France	34	2.8k 1.1×	2.7k 1.1×	134 0.3×	501 1.2×	22 0.1×	103	3.4k

Countries citing papers authored by Carlton Meschievitz

Since Specialization

Citations

This map shows the geographic impact of Carlton Meschievitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlton Meschievitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlton Meschievitz more than expected).

Fields of papers citing papers by Carlton Meschievitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlton Meschievitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlton Meschievitz. The network helps show where Carlton Meschievitz may publish in the future.

Co-authorship network of co-authors of Carlton Meschievitz

This figure shows the co-authorship network connecting the top 25 collaborators of Carlton Meschievitz. A scholar is included among the top collaborators of Carlton Meschievitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlton Meschievitz. Carlton Meschievitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ruben, Frederick L., James E. Froeschle, Carlton Meschievitz, et al.. (2001). Choosing a Route of Administration for Quadrivalent Meningococcal Polysaccharide Vaccine: Intramuscular versus Subcutaneous. Clinical Infectious Diseases. 32(1). 170–172. 15 indexed citations

DeFraites, Robert F., Jeffrey M. Gambel, C. H. Hoke, et al.. (1999). Japanese encephalitis vaccine (inactivated, BIKEN) in U.S. soldiers: immunogenicity and safety of vaccine administered in two dosing regimens.. American Journal of Tropical Medicine and Hygiene. 61(2). 288–293. 42 indexed citations

Vidor, Emmanuel, Carlton Meschievitz, & Stanley A. Plotkin. (1997). Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. The Pediatric Infectious Disease Journal. 16(3). 312–322. 45 indexed citations

Modlin, John F., et al.. (1997). Humoral and Mucosal Immunity in Infants Induced by Three Sequential Inactivated Poliovirus Vaccine-Live Attenuated Oral Poliovirus Vaccine Immunization Schedules. The Journal of Infectious Diseases. 175(Supplement 1). S228–S234. 70 indexed citations

Liese, Johannes G., Carlton Meschievitz, James E. Froeschle, et al.. (1997). Efficacy of a two-component acellular pertussis vaccine in infants. The Pediatric Infectious Disease Journal. 16(11). 1038–1044. 75 indexed citations

Rothstein, Edward, Hitoshi Kamiya, Tadashi Matsuda, et al.. (1996). Comparison of Diphtheria-Tetanus-Two Component Acellular Pertussis Vaccines in United States and Japanese Infants at 2, 4, and 6 Months of Age. PEDIATRICS. 97(2). 236–242. 17 indexed citations

Meschievitz, Carlton, et al.. (1995). Safety and Immunogenicity of PRP-T Combined with DTP: Excretion of Capsular Polysaccharide and Antibody Response in the Immediate Post-Vaccination Period. PEDIATRICS. 95(4). 522–527. 20 indexed citations

Ferreccio, Catterina, Rosanna Lagos, I Horwitz, et al.. (1993). Haemophilus influenzae type b polysaccharidetetanus protein conjugate vaccine does not depress serologic responses to diphtheria, tetanus or pertussis antigens when coadministered in the same syringe with diphtheria-tetanus-pertussis vaccine at two, four and six months of age. The Pediatric Infectious Disease Journal. 12(8). 638–643. 45 indexed citations

Feldman, Sandor, et al.. (1993). Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids.. PubMed. 86(3). 269–75, 284. 6 indexed citations

10.

Pichichero, Michael E., Anne Francis, Steven M. Marsocci, et al.. (1993). Safety and Immunogenicity of an Acellular Pertussis Vaccine Booster in 15- to 20-Month-Old Children Previously Immunized With Acellular or Whole-Cell Pertussis Vaccine as Infants. PEDIATRICS. 91(4). 756–760. 20 indexed citations

11.

Wald, Ellen R., et al.. (1992). Safety and immunogenicity of acellular diphtheria-tetanus-pertussis and Haemophilus conjugate vaccines given in combination or at separate injection sites. The Journal of Pediatrics. 120(1). 84–87. 16 indexed citations

12.

Causse, Xavier, P. Chossegros, Fabien Zoulim, et al.. (1991). Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology. 101(2). 497–502. 222 indexed citations

13.

Davis, Gary L., Eugene R. Schiff, Karen L. Lindsay, et al.. (1990). Treatment of chronic hepatitis C with recombinant α-interferon. A multicentre randomized, controlled trial. Journal of Hepatology. 11. S31–S35. 16 indexed citations

14.

Perrillo, Robert P., E. Schiff, Gerald L. Davis, et al.. (1990). A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B. New England Journal of Medicine. 323(5). 295–301. 664 indexed citations breakdown →

15.

Rosina, F., Giorgio Maria Saracco, Laura M. Giorda, et al.. (1989). ALPHA INTERFERON IN THE TREATMENT OF CHRONIC DELTA HEPATITIS. 21. 141–145. 10 indexed citations

16.

Davis, Gary L., Luis A. Balart, Eugene R. Schiff, et al.. (1989). Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa. New England Journal of Medicine. 321(22). 1501–1506. 1368 indexed citations breakdown →

17.

Hoofnagle, Jay H., Marion G. Peters, Kevin D. Mullen, et al.. (1988). Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B. Gastroenterology. 95(5). 1318–1325. 360 indexed citations

18.

Hoofnagle, Jay H., Marion G. Peters, Kevin D. Mullen, et al.. (1988). Randomized, Controlled Trial of Recombinant Human a-Interferon in Patients With Chronic Hepatitis B. 19 indexed citations

19.

Dick, E. C., et al.. (1986). Interruption of Transmission of Rhinovirus Colds Among Human Volunteers Using Virucidal Paper Handkerchiefs. The Journal of Infectious Diseases. 153(2). 352–356. 32 indexed citations

20.

D'Alessio, Donn, et al.. (1984). Short-Duration Exposure and the Transmission of Rhinoviral Colds. The Journal of Infectious Diseases. 150(2). 189–194. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact